Our Science

Addressing unmet medical needs

Our clinical-stage program, ALTB-168, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.

Our Scientific Approach

Pipeline

INNOVATIVE SOLUTIONS

AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.

Apr, 2024

ALTB-268

Inheriting the unique mechanism of action from ALTB-168, ALTB-268 is subtly designed as a tetravalent molecule to achieve better efficacy. From preclinical and phase 1 clinical studies ALTB-268 exhibits not only comparable safety profiles, but also improved potency in down-regulating chronic pathogenic T cells. Therefore, a lower dosage to obtain an equivalent efficacy in clinical is expected.
more
ALTB-168

ALTB-168 is a humanized therapeutic antibody with a unique mechanism of action, preferentially inducing the down regulation of late-stage, chronically activated T cells. This novel antibody effectively targets chronic pathogenic T cells while fully maintaining host defense, leading to durable clinical efficacy with a potential to reduce risks of adverse events such as infection and cancer. These two characteristics, which have been well demonstrated in our clinical studies, offer a sustainable competitive advantage over existing therapies.



ALTB-168 has demonstrated signs of clinical efficacy in Phase II clinical trials for T-cell mediated diseases such as psoriasis, psoriatic arthritis and ulcerative colitis. This innovative drug candidate has the potential to bring game-changing benefits to patients with many other T-cell mediated diseases. We have also completed a phase I study in patients who develop steroid/treatment-refractory acute graft versus host disease (SR/TR-GVHD) after allogeneic hematopoietic cell transplantation (HCT), as well as an ongoing clinical study in the front-line setting of acute GVHD.
more

Publications

more